There are currently 1248 clinical trials in Nashville, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University and Sarah Cannon Research Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
NCT05316584
Recruiting
The investigators hypothesize that use of a remote monitoring digital health system that supports medication taking and monitoring of symptoms will improve adherence, clinical outcomes, and decrease healthcare utilization compared to standard care in participants with inflammatory bowel disease initiating oral or subcutaneous treatment. The investigators are conducting a 12-month, multicenter, randomized, controlled trial to assess the feasibility and effectiveness of a remote monitoring digital... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/26/2023
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Register for Updates
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT01665794
Recruiting
The study will investigate the effects of adding carfilzomib to the combination of pomalidomide and dexamethasone in sequential dose escalation cohorts in patients with relapsed or refractory multiple myeloma. This portion of the study is complete. This study will also investigate the effects of adding daratumumab to the combination of carfilzomib, pomalidomide and dexamethasone.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2023
Locations: Sarah Cannon Research Institute, Nashville, Tennessee
Conditions: Multiple Myeloma
Register for Updates
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
NCT03662126
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF. This study will be conducted in 2 phases. Phase 2 will determine the KRT-232 recommended dose and dosing schedule; Phase 3 will test KRT-232 vs Best Available Therapy (BAT). Patients in the Phase 3 part of the study will be randomized 2:1 to receive ei... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2023
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
Register for Updates
A Study of DF6002 Alone and in Combination With Nivolumab
NCT04423029
Recruiting
The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and in combination with Nivolumab in participants with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2023
Locations: Local Institution, Nashville, Tennessee +1 locations
Conditions: Solid Tumors
Register for Updates
The Hancock Jaffe Surgical Antireflux Venous Valve Endoprosthesis Study
NCT04943172
Recruiting
A prospective, non blinded, single arm, multicenter study designed to assess the safety and effectiveness of the bioprosthetic, VenoValve, which is surgically implanted into the deep venous system for treatment of patients with deep venous valvular insufficiency ( C4b-C6 patients).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2023
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Deep Venous Insufficiency (Diagnosis)
Register for Updates
Auditory Neural Function in Implanted Patients With Usher Syndrome
NCT04906135
Recruiting
Usher syndrome (USH) causes extensive degeneration in the cochlear nerve (CN), especially in CN fibers innervating the base of the cochlea. As the first step toward developing evidence-based practice for managing implant patients with USH, this study evaluates local neural health, as well as the neural encoding of temporal and spectral cues at the CN in implanted patients with USH. Aim 1 will determine local CN health in patients with USH by assessing the sensitivity of the electrically evoked c... Read More
Gender:
All
Ages:
Between 1 year and 85 years
Trial Updated:
04/03/2023
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Usher Syndrome, Cochlear Implantation
Register for Updates
Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors
NCT00178932
Recruiting
The goals of this study are to replicate previous findings of genetic predictors of response to clozapine and other antipsychotic drugs.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/03/2023
Locations: Psychiatric Hospital at Vanderbilt, Nashville, Tennessee
Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression
Register for Updates
Mechanically Optimizing Cardiac Preload in Heart Failure Patients
NCT04338503
Recruiting
The purpose of the current study is to determine if partial balloon occlusion of the inferior vena cava can optimize cardiac pre-load and subsequently pulmonary pressures and cardiac output as a novel method to unload pulmonary edema and other symptoms of decompensated congestive heart failure. All products in this study are FDA approved and adhere to the specifications of the intended use.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/28/2023
Locations: Saint Thomas Heart, Nashville, Tennessee
Conditions: Heart Failure
Register for Updates
Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors
NCT04053673
Recruiting
RBN-2397 inhibits PARP7, an enzyme that is switched on by cancer stresses, such as the toxins in cigarette smoke. Cancer cells use PARP7 to hide from the immune system by stopping the cell from sending a signal (Type 1 interferon) that tells the immune system that something is wrong and to kill the cell. RBN-2397 has been shown in animal studies to inhibit tumor growth and also shuts down the "don't kill me" signal the tumor is sending to evade the immune system. As a PARP7 inhibitor RBN-2397 is... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2023
Locations: SCRI-Nashville/Tennessee Oncology, Nashville, Tennessee
Conditions: Solid Tumor, Adult
Register for Updates
Delirium Reduction With Ramelteon
NCT05069428
Recruiting
The overall purpose of this study is to identify a medication that might treat and/or prevent delirium in intensive care unit (ICU). Currently, there is no proven medical therapy for prevention or treatment of delirium. Ramelteon is a medication approved for insomnia. We hypothesize that ramelteon may help regulate the day/night cycle and decrease ICU delirium.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2023
Locations: Centennial Medical Center, Nashville, Tennessee
Conditions: Delirium
Register for Updates
A Study of Dexlansoprazole Delayed-Release Capsules to Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children
NCT02616302
Recruiting
The main aims of the study are to see the side effects of Dexlansoprazole treatment effectiveness of Dexlansoprazole treatment in children having symptomatic nonerosive gastroesophageal reflux disease (GERD). Participants will take Dexlansoprazole by mouth once daily for 12 weeks
Gender:
All
Ages:
Between 2 years and 11 years
Trial Updated:
03/15/2023
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Gastroesophageal Reflux Disease (GERD)
Register for Updates
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
NCT04683250
Recruiting
Phase 1 and 2 trial to study the safety, pharmacokinetics, and efficacy of TAS0953/HM06 in patients with advanced solid tumors with RET gene abnormalities. Phase 1 aims to determine the Maximum Tolerated Dose (MTD) and identify the Recommended Phase 2 Dose (RP2D) to be used in phase 2.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/02/2023
Locations: The Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee
Conditions: RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors
Register for Updates